Jim Wassil Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total value of $669,280.00. Following the completion of the sale, the chief operating officer now owns 205,695 shares in the company, valued at approximately $17,208,443.70. The trade was a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jim Wassil also recently made the following trade(s):

• On Monday, December 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $92.49, for a total value of $739,920.00.
• On Friday, November 1st, Jim Wassil sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $106.80, for a total value of $854,400.00.

Vaxcyte Trading Up 1.9 %

NASDAQ:PCVX traded up $1.56 during midday trading on Friday, hitting $84.86. 786,150 shares of the company were exchanged, compared to its average volume of 771,175. Vaxcyte, Inc. has a fifty-two week low of $53.83 and a fifty-two week high of $121.06. The company has a market capitalization of $10.58 billion, a PE ratio of -18.45 and a beta of 0.94. The company has a fifty day simple moving average of $93.19 and a 200 day simple moving average of $92.84.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period in the previous year, the company earned ($0.91) EPS. As a group, equities research analysts expect that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Riverview Trust Co acquired a new position in Vaxcyte during the third quarter worth $27,000. Blue Trust Inc. grew its stake in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after purchasing an additional 93 shares during the period. Meeder Asset Management Inc. increased its holdings in shares of Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock valued at $80,000 after purchasing an additional 635 shares in the last quarter. Nomura Asset Management Co. Ltd. acquired a new stake in shares of Vaxcyte in the third quarter valued at about $92,000. Finally, Quest Partners LLC acquired a new position in Vaxcyte during the second quarter worth about $70,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on PCVX shares. Mizuho lifted their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research report on Tuesday, September 10th. The Goldman Sachs Group initiated coverage on Vaxcyte in a research report on Friday, December 20th. They set a "buy" rating and a $135.00 price objective on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $140.00 target price on shares of Vaxcyte in a report on Wednesday, November 6th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Vaxcyte in a report on Wednesday, November 6th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte presently has a consensus rating of "Buy" and an average target price of $145.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.